Additionally, the T790 M mutation, oftentermed the secondary “guardian” mutation, enhances ATPbinding affinity and is common across different cancer types.5 As a result, EGFR has emerged as a crucial therapeutictarget in cancer treatment. The gene discussed is EGFR; the disease is cancer.